Abstract Submission Guidelines

Quick Links ♦ Expected Timeline ♦ Submission Content ♦ NEW This Year ♦ Presenting Author ♦ Previous Presentations/Publications ♦ Revisions and Withdrawals ♦ Informed Consent ♦ Funding ♦ Disclosures of Relevant Financial Relationships ♦ Structure

ACDS 37^th Annual Meeting – March 26, 2026; Denver, CO

Abstract Submissions for the ACDS 37^th Annual Meeting are now CLOSED

Submission Deadline: November 10^th, 2025, 11:59pm CT

 

Expected Timeline

September 8, 2025		Submissions OPEN
November 10, 2025		Submissions CLOSE
December 19, 2025		Submission status notifications sent

 

Submission Content

Topics submitted must be within the scope of the ACDS mission and be closely related to one or more of the following domains:

• Contact Dermatitis
• Atopic Dermatitis
• Occupational Dermatitis
• Drug-Induced Dermatitis
• Environmental Dermatitis
• Patch Testing

Submissions outside of these topics will not be considered.

 

NEW This Year

• Each presenting author is eligible to submit only one abstract or case study.
• Case studies will only be considered for poster presentation slots unless deemed otherwise by the planning committee.

 

Presenting Author

The primary author is highly encouraged to complete the submission process due to the following:

• One Presenting Author must be indicated for each submission
• Only the Presenting Author will receive correspondences pertaining to submission status, presentation type, date and time, as well as instructions for completing presentation obligations if accepted. As such, their name, address, telephone, and email address must be included during the submission process.
• Some award eligibility is dependent on the Presenting Author's attributes
• The Presenting Author is expected to attend the event. Submissions will be withdrawn if the Presenting Author is not registered by March 1, 2026.

 

Previous Presentations/Publications

Abstracts published as an article on or before January 1, 2026, may not be submitted for this competition. Abstracts that have been presented at the national meetings of other organizations should also not be submitted for consideration.

 

Informed Consent

Any studies involving human subjects must conform to the principles of the Declaration of Helsinki of the World Medical Association (Clinical Research 1966; 14:103) and must meet all the requirements governing informed consent of the country in which the research was performed.

 

Revisions and Withdrawals

Withdrawals and revisions must be received in writing to ACDS at info@contactderm.org by February 20, 2026. No changes can be submitted after that date.

 

Funding

Any funds used during the research should be disclosed within the abstract.

 

Disclosures of Relevant Financial Relationships

In accordance with the essentials and standards set forth by the Accreditation Council for Continuing Medical Education, as well as guidelines proposed by the Food and Drug Administration and endorsed by the American Medical Association, an author with a conflict of interest with the content of their abstract must disclose that conflict prior to presentation. A conflict of interest includes, but is not limited to, any relevant financial relationship in a company, product or procedure mentioned in the abstract or in the presentation to be given at the conference. A conflict in and of itself will not eliminate an abstract from consideration.

If an abstract is accepted as an oral presentation, all authors are required to complete a disclosure form upon request. Presenters will acknowledge any conflict of interests in their presentation slides or on posters.

 

Abstract Structure